InfuSystem Holdings, Inc. (INFU)
| Market Cap | 271.77M +39.9% |
| Revenue (ttm) | 143.34M +2.5% |
| Net Income | 8.54M +68.4% |
| EPS | 0.40 +68.9% |
| Shares Out | 19.92M |
| PE Ratio | 34.08 |
| Forward PE | 28.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,478 |
| Open | 13.44 |
| Previous Close | 13.40 |
| Day's Range | 13.44 - 13.72 |
| 52-Week Range | 7.29 - 14.02 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 16.83 (+23.34%) |
| Est. Earnings | Nov 3, 2026 |
About INFU
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ... [Read more]
Financial Performance
In 2025, InfuSystem Holdings's revenue was $143.44 million, an increase of 6.36% compared to the previous year's $134.86 million. Earnings were $6.63 million, an increase of 182.60%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INFU stock is "Strong Buy." The 12-month stock price target is $16.83, which is an increase of 23.34% from the latest price.
News
InfuSystem Holdings Transcript: Investor update
A leading healthcare services platform continues to expand beyond its oncology core into high-growth wound care and lymphedema markets, leveraging a robust payer contract portfolio and investments in technology to drive margin expansion and operational efficiency. Revenue and EBITDA margins are growing, supported by a strong balance sheet, disciplined acquisitions, and minimal Medicare exposure.
InfuSystem Holdings Slides: Investor update
InfuSystem Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
InfuSystem to Host Investor Webcast on September 24, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Host Investor Webcast on September 24, 2026.
InfuSystem price target raised to $20 from $12 at B. Riley
B. Riley raised the firm’s price target on InfuSystem (INFU) to $20 from $12 and keeps a Buy rating on the shares. The company’s profitable growth thesis is compounding following…
InfuSystem Holdings Earnings Call Transcript: Q2 2026
Record quarterly revenue and margin expansion were driven by strong Oncology and wound care growth, with significant margin improvement from the GE HealthCare contract restructuring. Outlook remains positive, with continued growth expected in core segments and stable EBITDA margins.
InfuSystem Holdings Earnings release: Q2 2026
InfuSystem Holdings released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
InfuSystem Holdings Slides: Q2 2026
InfuSystem Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
InfuSystem Holdings Quarterly report: Q2 2026
InfuSystem Holdings has published its Q2 2026 quarterly earnings report on August 4, 2026.
InfuSystem Announces Financial Results for Second Quarter 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Financial Results for Second Quarter 2026.
InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026.
InfuSystem announces $20M stock repurchase program
InfuSystem (INFU) announced that the company’s Board of Directors has approved a stock repurchase program authorizing the company to repurchase up to $20M of the company’s outstanding common stock sta...
InfuSystem Announces $20 Million Stock Repurchase Program
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces $20 Million Stock Repurchase Program.
InfuSystem Holdings Earnings Call Transcript: Q1 2026
First quarter 2026 saw a 3% revenue decline due to a contract restructuring, but pro forma revenue and adjusted EBITDA margin improved. Wound care revenue more than doubled, and the new ERP system went live, with cost savings expected in 2027.
InfuSystem Holdings Earnings release: Q1 2026
InfuSystem Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
InfuSystem Holdings Quarterly report: Q1 2026
InfuSystem Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
InfuSystem Announces Financial Results for First Quarter 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Financial Results for First Quarter 2026.
InfuSystem to Report First Quarter 2026 Financial Results on May 7, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report First Quarter 2026 Financial Results on May 7, 2026.
InfuSystem Holdings Proxy statement: Proxy filing
InfuSystem Holdings filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026.
InfuSystem trading halted, volatility trading pause
09:30 EST InfuSystem (INFU) trading halted, volatility trading pause
InfuSystem price target raised to $17.50 from $15 at Lake Street
Lake Street analyst Ben Haynor raised the firm’s price target on InfuSystem (INFU) to $17.50 from $15 and keeps a Buy rating on the shares. Although revenue fell below consensus…
InfuSystem price target raised to $15 from $14 at Roth Capital
Roth Capital raised the firm’s price target on InfuSystem (INFU) to $15 from $14 and keeps a Buy rating on the shares following “above-consensus” Q4 results. The firm cites higher…
InfuSystem Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw 7% revenue growth and record adjusted EBITDA, with strong cash flow and a 30% net debt reduction. 2026 guidance calls for 6%-8% revenue growth, stable margins, and continued focus on Patient Services and new product launches.
InfuSystem Holdings Annual report: Q4 2025
InfuSystem Holdings has published its Q4 2025 annual report on February 24, 2026.